Roivant Sciences Ltd (ROIV)

Number of days of payables

Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020
Payables turnover 0.27 0.45 0.56 0.29 0.44 0.58 0.57 0.51 0.61 0.29 0.17 0.06 0.26 0.37 0.11 0.17 0.10 —
Number of days of payables days 1,331.57 808.79 649.99 1,267.76 826.32 626.16 639.34 714.37 598.34 1,238.14 2,093.71 5,917.18 1,407.85 989.50 3,399.24 2,092.44 3,646.45 —

March 31, 2025 calculation

Number of days of payables = 365 ÷ Payables turnover
= 365 ÷ 0.27
= 1,331.57

The trend analysis of Roivant Sciences Ltd's number of days of payables over the period from December 31, 2020, to March 31, 2025, reveals fluctuations in the company's ability to pay its outstanding obligations to suppliers and vendors. The number of days of payables provides insights into how long, on average, the company takes to settle its accounts payable.

From December 31, 2020, to June 30, 2022, the number of days of payables showed a general increasing trend, indicating that the company was taking longer to pay its suppliers. However, from June 30, 2022, to December 31, 2024, there was a decreasing trend in the number of days of payables, suggesting an improvement in the company's ability to manage its payables efficiently.

The lowest number of days of payables was recorded on December 31, 2023, at 626.16 days, while the highest was on June 30, 2022, at 5,917.18 days. The significant fluctuations in the number of days of payables indicate potential changes in the company's payment policies, supplier relationships, or financial performance.

Overall, a decreasing trend in the number of days of payables is generally viewed positively, as it may indicate improved liquidity management and stronger vendor relationships. However, it is essential to evaluate this ratio in conjunction with other financial metrics to gain a comprehensive understanding of Roivant Sciences Ltd's financial health and operational efficiency.